Lawrence Klein

Lawrence Klein

Chief Executive OfficeratOruka Therapeutics· In proxies 2023–2025

Pay in FY2025+544% from the year before · Oruka Therapeutics stock +56.3% the same year

Lawrence Klein was paid $3.4M in FY2025 (Dec), up 544%. Oruka Therapeutics stock rose 56.3% that year.

Pay$100 in the stock at the end of FY23 → $276
Pay is from the Summary Compensation Table of each Oruka Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Oruka TherapeuticsPublic company · 2 yr
    • Chief Executive Officer2024 – Present · 2 yrStock in role +775%
  2. Dyne TherapeuticsPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  3. Jasper Therapeutics, Inc.Public company · 2 yr
    • Director2021 – 2023 · 2 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?